(NYSE: COV), a leading global provider of healthcare products, today
announced the launch of the HALO90 ULTRA Ablation Catheter,
the latest addition to the HALO family of catheters for the endoscopic
treatment of Barrett's esophagus.
Barrett's esophagus is a precancerous condition of the lining of the
esophagus caused by gastroesophageal reflux disease (GERD). Left
untreated, the backward flow of stomach contents such as acid and bile
into the esophagus can lead to injury and chronic inflammation of the
esophagus lining. A proportion of GERD patients are at risk of
developing Barrett's esophagus, which can lead to esophageal
adenocarcinoma, a lethal cancer with a five-year survival rate of
The HALO90 ULTRA Ablation Catheter is designed to be used
independently or in conjunction with the commercially available HALO90
and HALO60 Ablation Catheters, both smaller focal
devices, and the HALO360+ Ablation Catheter, a balloon-based
endoscopic ablation system for treating larger, circumferential areas of
Barrett's esophagus. The HALO90 ULTRA Ablation Catheter has
received the CE Mark and is currently available in the U.S. and Europe.
All HALO products are based on patented technology that carefully
controls the amount of energy delivered to the tissue to safely and
effectively remove the diseased tissue and facilitate the re-growth of
new, healthy tissue. Together, the products offer physicians a safe and
convenient solution for the removal of Barrett's esophagus.